Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of Sirukumab in Rheumatoid Arthritis (Extension of SIRROUND-D and SIRROUND-T)
2012-001176-10Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sirukumab in rheumatoid arthritis (RA), sponsored by Janssen Pharmaceutical. Primary endpoint: Cardiovascular serious adverse events. Started Jun 2013; status: completed.
02
Drugs
sirukumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2012-001176-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001176-10.